Systemic administration of the potential countermeasure huperzine reversibly inhibits central and peripheral acetylcholinesterase activity without adverse cognitive-behavioral effects

Pharmacology Biochemistry and Behavior

Volumn 94, Issue 3, 2010, Pages 477-481

  Myers, Todd M ^a   Sun, Wei ^b   Saxena, Ashima ^b   Doctor, Bhupendra P ^b   Bonvillain, Andrew J ^a   Clark, Matthew G ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Acetylcholinesterase inhibitor; Chemical warfare nerve agent therapy; Drug pharmacology; Operant behavior; Rhesus macaque (Macaca mulatta); Touch screen response; Visual recognition memory

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; HUPERZINE A; PHYSOSTIGMINE;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; MALE; MENTAL FUNCTION; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TASK PERFORMANCE; WORKING MEMORY;

ACETYLCHOLINESTERASE; ANIMALS; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; COGNITION; MACACA MULATTA; SESQUITERPENES;

MACACA MULATTA;

EID: 71849086794     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.10.011     Document Type: Article

References (37)

1. Anderson D.R., Harris L.W., Lennox W.J., and Solana R.P. Effects of subacute pretreatment with carbamate together with acute adjunct pretreatment against nerve agent exposure. Drug Chem Toxicol 14 (1991) 1-19
2. Bizot J.C. Effects of various drugs including organophosphorus compounds (OPC) and therapeutic compounds against OPC on DRL responding. Pharmacol Biochem Behav 59 (1998) 1069-1080
3. Chambers J.E., and Chambers H.W. Short-term effects of paraoxon and atropine on schedule-controlled behavior in rats. Neurotoxicol Teratol 11 (1989) 427-432
4. Cheng D.H., and Tang X.C. Comparative studies of huperzine A, E2020, and Tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 60 (1998) 377-386
5. Clark M.G., Sun W., Myers T.M., Bansal R., Doctor B.P., and Saxena A. Effects of physostigmine and human butyrylcholinesterase on acoustic startle reflex and prepulse inhibition in C57BL/6J mice. Pharmacol Biochem Behav 81 (2005) 497-505
6. Diamond B., Johnson S., Torsney K., Morodan J., Prokop B., Davidek D., et al. Complementary and alternative medicines in the treatment of dementia: an evidence-based review. Drugs Aging 20 (2003) 981-998
7. Dunn M.A., and Sidell E.R. Progress in medical defense against nerve agents. JAMA 262 (1989) 649-652
8. Dunn M.A., Hackley Jr. B.E., and Sidell F.R. Pretreatment for nerve agent exposure. In: Sidell F.R., Takafuji E.T., and Franz D.R. (Eds). Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R., and Bellamy R.F. (Eds). Textbook of Military Medicine (1997), Office of the Surgeon General at TMM Publications, Department of the Army USA, Washington, DC 181-196
9. Ellenhorn M.J. In: Schonwald S., Ordog G., and Wasserberger J. (Eds). Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Second Edition (1997), Williams & Wilkins, Baltimore, Maryland 1286-1287
10. Frederick D.L., Schulze G.E., Gillam M.P., and Paule M.G. Acute effects of physostigmine on complex operant behavior in rhesus monkeys. Pharmacol Biochem Behav 50 (1995) 641-648
11. Geller I., Hartmann R.J., Leal B.Z., Haines R.J., and Gause E.M. Effects of the irreversible acetylcholinesterase inhibitor soman on match-to-sample behavior of the juvenile baboon. Proc West Pharmacol Soc 27 (1984) 217-221
12. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005;15:157-158:239-46. Electronic publication 2005 Oct 26.
13. Grunwald J., Raveh L., Doctor B.P., and Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 54 (1994) 991-997
14. Harris L.W., Talbot B.G., Lennox W.J., Anderson D.R., and Solana R.P. Physostigmine (alone and together with adjunct) pretreatment against soman, sarin, tabun and VX intoxication. Drug Chem Toxicol 14 (1991) 265-281
15. Kerenyi S.Z., Murphy M.R., and Hartgraves S.L. Toxic interactions between repeated soman and chronic pyridostigmine in rodents. Pharmacol Biochem Behav 37 (1990) 267-271
16. Kluwe W.M. Efficacy of pyridostigmine against soman intoxication in a primate model. Proceedings of the Sixth Medical Chemical Defense Bioscience Review vol. 6 (1987), US. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland 227-234 AD Bl21516
17. Lallement G., Foquin A., Dorandeu F., Baubichon D., and Carpentier P. Subchronic administration of various pretreatments of nerve agent poisoning. II. Compared efficacy against soman toxicity. Drug Chem Toxicol 24 (2001) 165-180
18. Lallement G., Baille V., Baubichon D., Carpentier P., Collombet J.M., Filliat P., et al. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23 (2002) 1-5
19. Lallement G., Demoncheaux J.P., Foquin A., Baubichon D., Galonnier M., Clarencon D., et al. Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity. Drug Chem Toxicol 25 (2002) 309-320
20. Liu W.F. Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats. Neurotoxicol Teratol 22 (2000) 389-396
21. Mach M., Grubbs R.D., Price W.A., Paton S.J., and Lucot J.B. Behavioral changes after acetylcholinesterase inhibition with physostigmine in mice. Pharmacol Biochem Behav 79 (2004) 533-540
22. Marino M.T., Schuster B.G., Brueckner R.P., Lin E., Kaminskis A., and Lasseter K.C. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J Clin Pharmacol 38 (1998) 227-235
23. Myers T.M., and Clark M.G. Serial-probe recognition in rhesus macaques: effects of midazolam. Pharmacol Biochem Behav 85 (2006) 555-561 Electronic publication 2006 Dec 1
24. Ou L.Y., Tang X.C., and Cai J.X. Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys. Eur J Pharmacol 433 (2001) 151-156
25. Philippens I.H., Melchers B.P., and Wolthuis O.L. Active avoidance behavior in guinea pigs: effects of physostigmine and scopolamine. Pharmacol Biochem Behav 42 (1992) 285-289
26. Philippens I.H., Wolthuis O.L., Busker R.W., Langenberg J.P., and Melchers B.P. Side effects of physostigmine as a pretreatment in guinea pigs. Pharmacol Biochem Behav 55 (1996) 99-105
27. Preston K.L., Schuster C.R., and Seiden L.S. Methamphetamine, physostigmine, atropine and mecamylamine: effects on force lever performance. Pharmacol Biochem Behav 23 (1985) 781-788
28. Solana R.P., Gennings C., Carter Jr. W.H., Anderson D., Lennox W.J., Carchman R.A., et al. Evaluation of the efficacy of two carbamates, physostigmine and pyridostigmine, when used in conjunction for protection against organophosphate exposure. Fundam Appl Toxicol 15 (1990) 814-819
29. Tang X.C., and Han Y.F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Reviews 5 (1999) 281-300
30. Tang X.C., DeSarno P., Sugaya K., and Giacobini E. Effect of Huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24 (1989) 276-285
31. Tang X.C., Kindel G.H., Kozikowski A.P., and Hanin I. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol 44 (1994) 147-155
32. von Bredow J., Corcoran K., Maitland G., Kaminskis A., Adams N., and Wade J. Efficacy evaluation of physostigmine and anticholinergic adjuncts as a pretreatment for nerve agent intoxication. Fundam Appl Toxicol 17 (1991) 782-789
33. Wang H., and Tang X.C. Anticholinesterase effects of huperzine A, E2020 and tacrine in rats. Acta Pharmacologica Sinica 19 (1998) 27-30
34. Wang R., Yan H., and Tang X.C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 27 (2006) 1-26
35. Wetherell J., Hall T., and Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 23 (2002) 341-349
36. Ye J.W., Cai J.X., Wang L.M., and Tang X.C. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 288 (1999) 814-819
37. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav 75 (2003) 675-686